Edition:
India

Aurinia Pharmaceuticals Inc (AUPH.OQ)

AUPH.OQ on NASDAQ Stock Exchange Global Market

5.90USD
16 Aug 2019
Change (% chg)

-- (--)
Prev Close
$5.90
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
86,145
52-wk High
$7.84
52-wk Low
$5.07

Latest Key Developments (Source: Significant Developments)

Aurinia Pharmaceuticals Reports Qtrly Loss Per Share ‍of $0.04​
Friday, 16 Mar 2018 

March 15 (Reuters) - Aurinia Pharmaceuticals Inc ::AURINIA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.AURINIA PHARMACEUTICALS INC QTRLY LOSS PER SHARE ‍$0.04​.AURINIA PHARMACEUTICALS INC - ‍TRIALS IN FSGS AND DRY EYE TO BEGIN IN Q2 2018​.  Full Article

Aurinia reports Q3 loss per share $0.16
Wednesday, 15 Nov 2017 

Nov 14 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia reports third quarter 2017 financial results and provides operational highlights.Aurinia Pharmaceuticals Inc - ‍Aurora phase III trial in lupus nephritis on track​.Q3 loss per share $0.16.Aurinia Pharmaceuticals - Believe​ co have sufficient financial resources to fund LN program,conduct work on new indications & fund operations into 2020.  Full Article

Robert Duggan reports 5.9 pct stake in Aurinia Pharmaceuticals - SEC filing‍​
Tuesday, 24 Oct 2017 

Oct 23 (Reuters) - Aurinia Pharmaceuticals Inc : :Robert Duggan reports 5.9 percent stake in Aurinia Pharmaceuticals Inc as on October 19, 2017 - SEC filing‍​.Robert Duggan had previously reported 7.2 percent stake in Aurinia Pharmaceuticals Inc as on April 21, 2017.  Full Article

Aurinia Pharmaceuticals plans to expand voclosoprin renal franchise
Friday, 20 Oct 2017 

Oct 20 (Reuters) - Aurinia Pharmaceuticals Inc :Aurinia Pharmaceuticals Inc - ‍ plans to expand voclosoprin renal franchise to include focal segmental glomerulosclerosis and minimal change disease​.Aurinia Pharmaceuticals - ‍ plans to evaluate proprietary nanomicellar voclosporin ophthalmic solution for treatment of keratoconjunctivitis sicca/ DES.Aurinia Pharmaceuticals - ‍a phase II proof of concept clinical trial for voclosporin in FSGS and MCD patients will be initiated in first half of 2018​.  Full Article